Efficacy and tolerability of Lu177-PSMA in pretreated older Veterans with less favorable performance status (AVAHO 2026) - Oct 11, 2026 - Abstract #19; Pres time: Sep 11, 2026; 02:15 PM - 03:15 PM; "Background: Lutetium177-PSMA-617 (Lu177) is a radioligand therapy for PSMA-positive metastatic castrate resistant prostate cancer (mCRPC) after receipt of at least one androgen receptor pathway inhibitor (ARPI)... Median patient age was 76.5. 79% were white, 58.3% had Gleason score of 8-10, and 75% received ≥3 prior lines of treatment. Of nine taxane naïve patients, eight received ≥2 prior systemic therapies."
Clinical • Asthma • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Heart Failure • Immunology • Infectious Disease • Musculoskeletal Diseases • Prostate Cancer • Respiratory Diseases • Solid Tumor
|